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INTRODUCTION: 
The term prodrug refers to a pharmacologically inactive 
compound that is converted to an active drug by a 
metabolic biotransformation which may occur prior, 
during and after absorption or at specific target sites 
within the body.
1 The concept of “prodrug” was first 
introduced by Adrian Albert in 1958 to describe 
compounds that undergo biotransformation prior to 
eliciting their pharmacological effect i.e. "therapeutic 
agents that are inactive but can be transformed into one 
or more active metabolites." The prodrug design 
approach is also referred to as “Drug Latentiation”.2 
 
Figure 1: Fate of prodrug approach 
Almost all the drugs possess undesirable 
physiochemical and biological properties such as poor 
bioavailability, incomplete absorption, adverse effects, 
first pass metabolism etc. The therapeutic efficacy of 
these drugs can be easily improved by eliminating the 
above discussed problems and these problems can be 
removed by using physical, chemical or biological 
means. The physical means include introduction of 
controlled release formulation such as sustained release, 
prolong release formulation etc. The biological 
approach is to alter the route of administration which 
may or may not be acceptable to patient. The third and 
the last approach is the chemical means which include 
introduction of prodrug which is best among physical 
and biological means. 
3
 
OBJECTIVES OF PRODRUG DESIGN 
4
:  
Pharmaceutical objectives: 
 To improve solubility (e.g., corticosteroids). 
 To improve chemical stability (e.g., dopamine). 
 To improve organoleptic properties (e.g, 
chloramphenicol palmitate is sparingly soluble 
prodrug of chloramphenicol,which is practically 
tasteless due to its low aqueous solubility as well as 
it is hydrolysed to active chloramphenicol by the 
action of pancreatic lipase).  
 To decrease irritation and pain. 
2. Pharmacokinetic objectives: 
 To improve oral absorption or permeability and 
thus increase 
bioavailability(ampicillin,Epinephrine), 
 To decrease first pass metabolism (propanolol).  
 To improve absorption by non oral routes. 
 To provide organ or tissue selective delivery of 
active agent.     
3. Pharmacodynamics objectives: 
 To avoid adverse effects or toxicities.  
 To mask reactive species to improve its therapeutic 
index.  
 To improve site specificity (i.e., that the site of 
action of an active drug is rather nonspecific such 
as anticancer agents). 
 
ABSTRACT 
Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or chemical transformation in vivo to 
release the active parent drug, which can then exert the desired pharmacological effect. Prodrug design is a choice of approach 
in solving many of the problems like stability, toxicity, solubility, permeability and drug targeting that affect drug discovery 
and development. Prodrug design is fruitful approach for drug targeting by changing the physiochemical, biopharmaceutical or 
pharmacokinetic properties of drugs. About 10-14% of drugs approved worldwide can be classified as prodrugs. The present 
article takes a review of introduction, classification, applications of prodrug design in various areas of drug development and 
basic functional groups that are amenable to prodrug design. 
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Parajuli et al                                           Journal of Drug Delivery & Therapeutics. 2015; 5(3):5-9 6 
© 2011-15, JDDT. All Rights Reserved                                                    ISSN: 2250-1177                                            CODEN (USA): JDDTAO 
CLASSIFICATION OF PRODRUGS: 
5
 
Depending upon constitution, lipophilicity, method of 
bioactivation and catalyst involved; prodrugs are 
classified into two groups. 
A. Carrier – linked prodrugs. 
B. Bio precursor prodrug. 
1. Carrier linked prodrug: 
It contains a group that can be easily removed 
enzymatically (such as ester) to reveal the true drugs. 
Ideally the group removed is pharmacologically 
inactive and nontoxic while the connecting bond must 
be labile for efficient activation in vivo. Carrier linked 
prodrug consists of the attachment of a carrier group to 
the active drug to alter its physicochemical properties. 
Depending upon the nature of carrirer used it can be 
classified as: 
a) Bipartate Prodrug or Double prodrugs or 
cascade-latentiated prodrug: 
This prodrug consists of the active drug covalently 
linked to an inert carrier or transport moiety, generally 
ester or amide. Such prodrugs have greatly modified 
lipophilicity due to the attached carrier. The active drug 
is released by hydrolytic cleavage either chemically or 
enzymatically. The Prodrug and carrier released after in 
vivo enzymatical or non-enzymatical attack must be 
nontoxic. 
b) Tripartate Prodrug: 
In this the drug moiety is not directly attached to the 
carrier moiety.  
 
 
First the drug moiety is attached with the linker and 
then this linker is attached with carrier. 
c. Macromolecular prodrugs: 
Where macromolecules like polysaccharides, dextrans, 
cyclodextrins, proteins, peptides and polymers are used 
as carriers. 
d. Site- specific prodrugs: 
Where a carrier acts as a transporter of the active drug 
to a specific targeted site. 
e. Mutual prodrug: 
Where the carrier used is another biologically active 
drug instead of some inert molecule. A mutual prodrug 
consists of two pharmacologically active agents coupled 
together so that each acts as a promoiety for the other 
agent and vice versa. The carrier selected may have the 
same biological action as that of the parent drug and 
thus might give synergistic action, or the carrier may 
have some additional biological action that is lacking in 
the parent drug, thus ensuring some additional benefit. 
The carrier may also be a drug that might help to target 
the parent drug to a specific site or organ or cells or 
may improve site specificity of a drug. The carrier drug 
may be used to overcome some side effects of the 
parent drugs as well. 
2. Bioprecursor/Metabolic precursor: 
This approach does not include any carrier molecule. In 
this an inactive drug undergoing chemical modification 
to convert into a compound which itself is active drug 
or further metabolized into active form which have a 
desired therapeutic efficacy. The chemical reaction 
occurs in this process include oxidation or 
reduction.(e.g. amine to aldehyde to carboxylic acid). 
 
 
 
Parajuli et al                                           Journal of Drug Delivery & Therapeutics. 2015; 5(3):5-9 7 
© 2011-15, JDDT. All Rights Reserved                                                    ISSN: 2250-1177                                            CODEN (USA): JDDTAO 
New classification: Based on cellular site of 
bioactivation: 
Prodrugs can be classified into two major types, based 
on their cellular sites of bioactivation into the final 
active drug form with Type I being those that are 
bioactivated intracellularly (e.g.,anti-viral nucleoside 
analogs, lipid-lowering statins) and Type II being those 
that are bioactivated extracellularly, especially in 
digestive fluids or the systemic circulation (e.g., 
etoposide phosphate, valganciclovir, fosamprenavir, 
antibody-, gene- or virus-directed enzyme prodrugs 
[ADEP/GDEP/VDEP] for chemotherapy or 
immunotherapy). Both types can be further categorized 
into Subtypes, i.e. Type IA, IB and Type IIA, IIB and 
IIC based on whether or not the intracellular 
bioactivating location is also the site of therapeutic 
action, or the bioactivation occurs in the GI fluids or 
systemic circulation. 
6
 
FUNCTIONAL GROUPS AMENABLE TO 
PRODRUG DESIGN 
7
: 
Ideally, the design of an appropriate prodrug structure 
should be considered at the early stages of preclinical 
development, bearing in mind that prodrugs might alter 
the tissue distribution, efficacy and the toxicity of the 
parent drug. Several important factors should be 
carefully examined when designing a prodrug structure, 
including 
Parent drug:  
Which functional groups are amenable to chemical 
prodrug derivatization. 
Promoiety: 
This should ideally be safe and rapidly excreted from 
the body. The choice of promoiety should be considered 
with respect to the disease state, dose and the duration 
of therapy. 
Parent and prodrug: 
The absorption, distribution, metabolism, excretion and 
pharmacokinetic properties need to be comprehensively 
understood. 
Some of the most common functional groups that are 
amenable to prodrug design include carboxylic, 
hydroxyl, amine, phosphate/phosphonate and carbonyl 
groups. Prodrugs typically produced via the 
modification of these groups include esters, carbonates, 
carbamates, amides, phosphates and oximes. 
PRODRUG INCORPORATED DRUG 
DELIVERY:
8,9
 
The colloidal drug delivery system works as a 
controlled and sustained delivery by releasing the 
encapsulated drug while in circulation or after the 
recognition by cell, so it is necessary that the delivery 
system must contain maximum quantity of drug for 
optimum efficacy. 
Liposome: Liposomes consists of lipid bilayer in which 
between lipid bilayer intervening water molecules are 
present. The drug is incorporated into either aqueous 
compartment or in the lipid bilayer as the drug has its 
physicochemical property. The less hydrophobic drug 
exhibit low entrapment efficiency and making them 
more hydrophobic by derivative of fatty acids, improves 
the entrapment efficiency of delivery system e.g. the 
tramcinolone palmitate (prodrug) showed 85% 
entrapment efficiency as compared to triamcinolone 
acetonite which has 5% entrapment efficiency. 
Liporotein: Lipoprotein are endogenous transporter of 
lipids in the circulation, they are nonimmunogenic 
escapes recognition by reticuloendothelial system. Their 
structural components are Neo HDL particles consisting 
of nonpolar triglyceride core surrounded by 
phospholipids monolayer in which specific apoprotein 
are imbedded. Since apoprotein are necessary for the 
recognition of LDL so drug should be into the lipid 
moiety but most of the drug has not sufficient lipophilic 
so there is need to prepare lipophilic prodrug. 
Emulsion: The oil in water emulsion are used as 
sustained drug delivery, by passing targeted to 
macrophages and active targeting by ligand attachment, 
so in this case the lipophlicity of the drug is necessary 
to make as oil in water emulsion as sustained delivery 
system e.g. Esterified phenolic hydroxy derivative of 
etoposide is used as lipophilic prodrug which is soluble 
in lipid emulsion in which cholesteryl ester oil used as 
oil component. 
Soild Lipid Nanoparticle: Solid lipid nanoparticle 
consisted of high melting point triglyceride as the solid 
core phospholipids coating. Its advantage over the other 
system is use of natural lipid and incorporation of drug 
in triglyceride core which may be applicable for 
prolonged release. For prolonged release it is desirable 
to incorporate the drugs into triglyceride phase of 
emulsion e.g. Azidothymidine palmitate ester prodrug 
incorporation increases as compared to Azidothymidine 
cleavage. 
Methods of Evaluation of Prodrugs 
10, 11 
The pharmacokinetics (ADME) of drug is greatly 
influenced by physicochemical properties such as 
solubility, lipophilicity, pH, surface area, molecular 
weight of molecule. Out of this pH, solubility and 
Lipophilicity are the key factors in determining in vivo 
behavior of drugs.    
Solubility Measurement: The solubility measurement 
is carried out by placing an excess amount of mutual 
prodrug in separate vials containing different solvents 
like 10 ml deionized water, n-hexane, phosphate buffer 
of different pH etc and then stirring at 37
o
C for 24 
hours. The solutions are centrifuged for 5 min at 900 
RPM and the supernatant is filtered with cellulose 
acetate membrane filters. The mutual prodrug 
concentration in each filtrate is determined by suitable 
analytical technique like HPAE-PAD/UV 
spectroscopy/HPLC after the appropriate dilution.    
Determination of Partition Coefficients: The partition 
coefficient between water or buffer and n-octanol or 
cyclohexane is the most widely used measure of 
chemical compound lipophilicity. Lipophilicity is a 
major structural factor governing both pharmacokinetics 
and pharmacodynamics of drugs. The partition 
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coefficient of a chemical compound provides 
ammonium ions. Because the pH of urine in the bladder 
is mildly acidic, methenamine is used as a urinary tract 
antiseptic. To prevent hydrolysis of this prodrug in the 
acidic environment of the stomach the tablets are 
enteric coated.  
In vitro pH Hydrolysis study: Hydrolysis studies are 
carried out in aqueous buffer so as to study whether the 
prodrug hydrolyzes in an aqueous medium and to what 
extent or not, suggesting the fate of mutual prodrug in 
the system. The kinetics of hydrolysis is monitored by 
the increase of free drug concentration with time and 
the order of the reaction and half-life (t
1/2
) are 
calculated.  
APPLICATIONS OF PRODRUGS: 
1. Anticancer agents: 
Chemotherapeutic agent Paclitaxel was attached to poly 
(hydroxyl ethyl aspartamide) via a succinic spacer arm 
by a two-step protocol:synthesis of 2′-O-succinyl-
paclitaxel; and synthesis of PHEA-2′-O- succinyl-
paclitaxel. Investigation carried out using murine 
myeloid cell line showed that the polymeric prodrug 
maintains partial pharmacological activity of paclitaxel. 
The conjugate disappeared from the bloodstream much 
more quickly as compared to both free drug and naked 
polymer. 
12
 
2. In GIT problem: colon targeting:  
For e.g. sulphasalazine which is formed by coupling of 
diazotized sulphanilamide pyridine with 5-amino 
salicylic acid. On oral administration intact 
sulphasalazine reaches the colon. The azo reductase 
associated with colonic microflora convert 
sulphasalazin to its constituents entities, the active 
species 5ASA available for absorption in colon, while 
precolonic absorption responsible for side effects is 
reduced. 
13
 
3. Immunomodulators: 
Leflunomide is a novel immunomodulatory agent which 
exhibits a strong anti-inflammatory action. It is potent 
therapeutic agent in autoimmune diseases, graft 
rejection, and tumour therapy. It is isoxazole derivative 
as a prodrug and is completely converted to its active 
metabolite which blocks the dihydroorotate 
dehydrogenase, a key enzyme of the pyrimidine de 
novo synthesis. 
12
 
4. Anti-Tubercular agents: 
Ethambutol (EB), isoniazid (INH) and p-amino salicylic 
acid (PAS) are potent antitubercular agents having 
various side effects due to formation of toxic 
metabolites. Mutual prodrugs of EB with PAS (PE), 
PAS with PAS (PP) and INH with PAS (PI) were 
synthesized and characterized. In vitro hydrolysis 
studies in SGF and SIF reveal that these mutual prodrug 
conjugates do not hydrolyze appreciably and are 
absorbed unhydrolyzed. In vivo studies showed greater 
serum concentrations of EB, PAS and INH than their 
concentrations when given alone and isoniazid 
concentrations were greater except for PP. Mutual 
prodrugs PI and PE significantly eliminate the problem 
of fast metabolism, toxicity and local irritation and 
reduction of therapeutic doses. 
14 
 
 
           PE      PP     PI 
 
5. CNS delivery:  
The only prodrug that is used clinically for entering the 
brain predominantly through LAT1-mediated transport is 
L-dopa. The neurotransmitter dopamine is not able to 
cross the BBB due to its hydrophilic nature. However, 
the conversion of dopamine into its α-amino acid, L-
dopa, enables the brain to uptake dopamine via LAT1. L-
Dopa is decarboxylated into dopamine by L-amino acid 
decarboxylase in the brain tissue and also in the 
peripheral circulation. Although approximately 95% of 
L-dopa is metabolized to dopamine in the peripheral 
tissues, the percentage of remaining L-dopa has been 
therapeutically enough to apply this approach in clinic 
practice for more than 30 years. 
15
 
6. Ocular delivery: 
The drug pilocarpine was converted to its ester prodrug 
forms. Pilocarpic acid diester and monoester prodrug 
solution showed significant biological activity and longer 
duration of action than pilocarpine. 
12
 
7.  For treating hypotension:  
L-Threo-3,4-dihydroxyphenylserine (droxidopa) is a 
norepinephrine (NE) prodrug under development to treat 
orthostatic hypotension. 
16
 
8. Cholesterol-lowering prodrug : 
Simvastatin (SV) is a lactone prodrug which undergoes 
reversible metabolism. In the hydroxy acid form (SVA) 
it is a potent inhibitor of HMG-CoA reductase. 
17 
LIMITATIONS OF PRODRUG DESIGN: 
18
 
As prodrug design has proven highly beneficial in 
overcoming various undesirable properties of drugs, it 
can also give rise to a large number of newer difficulties, 
especially in the assessment of pharmacological, 
pharmacokinetic, toxicological and clinical properties. 
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Problems at the pharmacological level: These 
compounds cannot be submitted to preliminary in vitro 
screening tests like binding studies, reuptake of 
neurotransmitter and enzyme inhibition measurement 
because bioactivation to their active species is necessary.  
Problems at the toxicological level: Formation of toxic 
metabolite, consumption of vital constituent during 
prodrug activation process, release of a pharmacokinetic 
modifier which may cause enzyme induction or alter 
drug excretion are certain toxicity mechanism of prodrug 
which is not produced by the parent drugs. 
Problems at the pharmacokinetic Studies: The mutual 
prodrug may not be an ideal substrate for the activating 
enzymes. Pharmacokinetic studies may lead to numerous 
misinterpretations. When mutual prodrug and parent 
molecules are being compared, one must take into 
account the differences in their respective time courses 
of action. The maximum activity may appear later for 
mutual prodrug than for parent compounds, so AUC 
should be compared as it presents a better criterion for 
comparison.  
Problems at the clinical stage: The predictive value of 
animal experiments is also questionable. The active 
doses of two mutual prodrugs of the same parent drugs 
may appear to be same in rats but may be quite different 
in clinical investigations. 
CONCLUSION:  
The prodrug strategy is one of the most promising 
approaches to enhance the therapeutic efficacy and/or 
reduce the adverse effects of the pharmacologically 
active agents via different mechanisms, including 
increased solubility, stability, improved permeability and 
bioavailability and tissue-targeted delivery. Hence, 
prodrugs are becoming a novel approach of the drug 
discovery paradigm. Despite the remarkable progress 
made in the field of prodrug design, more studies are 
clearly needed, especially at early stages of the drug 
discovery, for prodrugs to achieve the desired state of art 
and take their place in modern pharmacotherapy.  
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